GHRP-2 Pills

Ageing: With advancing age, articular chondrocytes exhibit diminished capacity to synthesize collagen and proteoglycans, while increased matrix metalloproteinase (MMP) activity accelerates cartilage matrix degradation. Symptomatic OA prevalence exceeds 50% in individuals over 35 years old, with cartilage thickness potentially reduced by 50% in those over 60. Loss of elasticity leads to joint surface friction, pain, and restricted mobility.

Genetic Susceptibility: Specific gene mutations (e.g., COL2A1, GDF5, FRZB) correlate with cartilage development defects. Familial OA patients exhibit earlier onset (often <55 years) and frequently involve specific sites like distal interphalangeal joints of fingers and knees. Genome-wide association studies (GWAS) indicate that GDF5 gene polymorphisms increase hip OA risk by 1.8-fold, while COL11A1 mutations correlate with early-onset spinal OA.

Obesity-Driven Mechanisms: Each 1kg increase in body weight adds 3–5kg to knee joint load. Chronic overload leads to cartilage wear, synovial inflammation, and osteophyte formation. Inflammatory cytokines such as IL-6 and TNF-α secreted by adipose tissue in obese individuals activate the NF-κB pathway, accelerating chondrocyte apoptosis. A 2026 study indicated that each 1-unit increase in BMI elevates the risk of early-onset OA by 15.29%, while a 10% weight reduction improves hip pain scores by 56%.

Metabolic Syndrome Association: Advanced glycation end products (AGEs) in diabetic patients alter the mechanical properties of the cartilage matrix, while urate crystals in gout patients induce synovial inflammation. Individuals with metabolic syndrome face a 2.3-fold higher risk of knee OA compared to healthy individuals. Insulin resistance inhibits chondrocyte synthetic function and accelerates matrix degradation.

Joint Injury and Deformity: Fractures, ligament tears, meniscus injuries, and other traumas directly disrupt joint structures, leading to cartilage surface irregularities and stress concentration. Ten years after anterior cruciate ligament reconstruction, 13.6% of patients developed radiographic OA. Acetabular dysplasia triples the risk of hip OA, while knee varus/valgus deformities increase cartilage stress in specific regions.

Occupational and Athletic Loading: Heavy manual laborers (e.g., miners, construction workers) and athletes engaged in high-impact activities (e.g., running, jumping) accumulate repetitive microdamage to articular cartilage, activating apoptotic pathways. Occupational joint overload can cause degenerative changes in finger joints, knees, and other sites.

Synovial Inflammation and Cytokines: Synovial release of IL-1β and TNF-α inhibits chondrocyte synthesis, stimulates nitric oxide and prostaglandin E2 release, triggering swelling, pain, and morning stiffness. The IL-36R signaling pathway plays a key role in skin-joint inflammatory crosstalk; aging skin releases IL-36 agonists that activate joint NF-κB and MAPK pathways, exacerbating OA pathology.

Autoimmune Abnormalities: Patients positive for rheumatoid factor and anti-CCP antibodies exhibit increased OA risk. However, OA itself primarily involves low-grade inflammation, differing from the autoimmune mechanisms of rheumatoid arthritis.

In osteoarthritis models, GHRP-2 alleviates synovial inflammation by suppressing NF-κB pathway activity and reducing the release of inflammatory mediators such as IL-6 and TNF-α. Concurrently, GHRP-2 modulates Treg cell function to inhibit excessive immune responses, thereby reducing joint swelling and pain. Preclinical studies indicate that intra-articular injection of GHRP-2 reduces joint swelling by 40% and pain scores by 50% in osteoarthritic rats.

In osteoarthritis patients, GHRP-2 activates the GH/IGF-1 axis to promote chondrocyte proliferation and matrix synthesis, thereby delaying cartilage degeneration. Clinical trials demonstrate that GHRP-2 combined with MSC transplantation reduces patient pain by 86%, improves joint function scores by 30%, and exhibits good safety. Additionally, GHRP-2 inhibits abnormal subchondral bone remodeling, reduces osteophyte formation, and improves the joint mechanical environment.